CITALOPRAM
Anxiety Disorders
Tianjin Medical University General HospitalSmall moleculePhase 4 / ApprovedDormant
BBB
74/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 60/ 100
- Competitive Position
- 95/ 100
Competitive context
5 Active assets in the Anxiety Disorders cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cipralex Tianjin Medical University General Hospital | Phase 4 | A |
Olanzapine Tianjin Medical University General Hospital | Phase 4 | BBB |
Vortioxetine H. Lundbeck A/S | Phase 4 | BB |
Rotigotine Johns Hopkins University | Phase 4 | BB |
Seroquel® Hannover Medical School | Phase 3 | BB |
View all 50 →
Same molecule, other indications
CITALOPRAM is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →